GeoVax Labs Inc (GOVX) - Total Liabilities
Based on the latest financial reports, GeoVax Labs Inc (GOVX) has total liabilities worth $1.82 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
GeoVax Labs Inc - Total Liabilities Trend (1996–2024)
This chart illustrates how GeoVax Labs Inc's total liabilities have evolved over time, based on quarterly financial data. See GeoVax Labs Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
GeoVax Labs Inc Competitors by Total Liabilities
The table below lists competitors of GeoVax Labs Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ZW Data Action Technologies Inc
NASDAQ:CNET
|
USA | $5.09 Million |
|
Awilco Drilling PLC
OL:AWDR
|
Norway | Nkr8.90 Million |
|
POB AG NA O.N.
XETRA:PO1
|
Germany | €4.19 Million |
|
Artelo Biosciences Inc
NASDAQ:ARTL
|
USA | $4.07 Million |
|
Marna Beteiligungen AG
F:M5S
|
Germany | €392.26K |
|
Zoomcar Holdings Inc.
NASDAQ:ZCAR
|
USA | $47.97 Billion |
|
Atlantis S.A.
WAR:ATS
|
Poland | zł24.00K |
|
Foresight VCT PLC
LSE:FTV
|
UK | GBX2.16 Million |
Liability Composition Analysis (1996–2024)
This chart breaks down GeoVax Labs Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of GeoVax Labs Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GeoVax Labs Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GeoVax Labs Inc (1996–2024)
The table below shows the annual total liabilities of GeoVax Labs Inc from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.11 Million | -11.72% |
| 2023-12-31 | $3.52 Million | -25.87% |
| 2022-12-31 | $4.75 Million | -36.14% |
| 2021-12-31 | $7.43 Million | +801.21% |
| 2020-12-31 | $825.00K | -59.63% |
| 2019-12-31 | $2.04 Million | +22.80% |
| 2018-12-31 | $1.66 Million | +105.10% |
| 2017-12-31 | $811.29K | +119.36% |
| 2016-12-31 | $369.85K | +191.24% |
| 2015-12-31 | $126.99K | -32.10% |
| 2014-12-31 | $187.02K | -40.12% |
| 2013-12-31 | $312.35K | -4.49% |
| 2012-12-31 | $327.04K | -65.27% |
| 2011-12-31 | $941.53K | +80.51% |
| 2010-12-31 | $521.61K | -8.71% |
| 2009-12-31 | $571.37K | +64.93% |
| 2008-12-31 | $346.42K | -42.12% |
| 2007-12-31 | $598.54K | +209.94% |
| 2006-12-31 | $193.11K | -96.67% |
| 2005-12-31 | $5.79 Million | +16.68% |
| 2004-12-31 | $4.97 Million | +24.46% |
| 2003-12-31 | $3.99 Million | +294.83% |
| 2002-12-31 | $1.01 Million | -45.92% |
| 2001-12-31 | $1.87 Million | +192.00% |
| 2000-12-31 | $639.91K | -77.31% |
| 1999-12-31 | $2.82 Million | -26.46% |
| 1998-12-31 | $3.83 Million | +140.62% |
| 1997-12-31 | $1.59 Million | +414.11% |
| 1996-12-31 | $309.96K | -- |
About GeoVax Labs Inc
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marb… Read more